Praxis Investment Management Inc. Sells 1,340 Shares of Axon Enterprise, Inc $AXON

Praxis Investment Management Inc. decreased its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 49.6% during the fourth quarter, HoldingsChannel reports. The fund owned 1,360 shares of the biotechnology company’s stock after selling 1,340 shares during the quarter. Praxis Investment Management Inc.’s holdings in Axon Enterprise were worth $772,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Axon Enterprise by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock valued at $5,319,928,000 after acquiring an additional 53,060 shares during the period. Baillie Gifford & Co. raised its holdings in Axon Enterprise by 1,198.7% during the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after acquiring an additional 1,516,099 shares during the period. Jennison Associates LLC raised its holdings in Axon Enterprise by 53.8% during the 3rd quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock valued at $677,412,000 after acquiring an additional 330,213 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in Axon Enterprise by 23.0% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 838,289 shares of the biotechnology company’s stock valued at $476,089,000 after acquiring an additional 156,647 shares during the period. Finally, Northern Trust Corp raised its holdings in Axon Enterprise by 1.6% during the 3rd quarter. Northern Trust Corp now owns 743,926 shares of the biotechnology company’s stock valued at $533,871,000 after acquiring an additional 11,726 shares during the period. Institutional investors own 79.08% of the company’s stock.

Insider Buying and Selling

In related news, Director Erika Nardini sold 198 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $506.58, for a total value of $100,302.84. Following the completion of the transaction, the director directly owned 1,946 shares in the company, valued at approximately $985,804.68. The trade was a 9.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeri Williams sold 157 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $490.00, for a total transaction of $76,930.00. Following the completion of the transaction, the director owned 1,159 shares of the company’s stock, valued at $567,910. This trade represents a 11.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 13,855 shares of company stock valued at $7,109,828 in the last three months. 4.40% of the stock is owned by corporate insiders.

Key Stories Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Company raised 2026 revenue growth guidance to 30%–32% and is targeting about $450M in free cash flow, signaling stronger cash conversion and confidence in demand. Axon raises 2026 revenue growth outlook to 30%-32% while targeting about
• Positive Sentiment: AI and counter?drone businesses surged: AI product revenue reported up ~700% Y/Y and counter?drone bookings/revenue rose several hundred percent, providing a new, high?growth revenue stream beyond Taser and cameras. Axon Raises Guidance With AI Revenue Up 700%
• Positive Sentiment: Q1 revenue beat: revenue of ~$807M (+34% Y/Y) and strong bookings/ARR commentary underpin the company’s claim of durable growth across software, devices and international markets. Axon reports Q1 2026 revenue of $807 million, up 34% year over year
• Positive Sentiment: Analyst bullishness: JPMorgan raised its price target and kept an overweight stance, reflecting confidence from at least one major sell?side shop. Benzinga: JPMorgan raises PT to $755
• Neutral Sentiment: Some brokers maintained Buy ratings and high targets (Needham, William Blair), signalling continued conviction but no consensus on valuation. Axon Maintained at Buy as Strong Growth Outlook Supports Unchanged $600 Price Target
• Neutral Sentiment: Media pieces are debating valuation — analysts’ average recommendations skew optimistic, so investors should weigh runway (AI/counter?drone) against a stretched multiple. Is Axon (AXON) a Buy as Wall Street Analysts Look Optimistic?
• Negative Sentiment: EPS/margin noise: some reports flagged an EPS miss or tariff?driven margin pressure despite revenue strength, which tempers the beat and raises near?term margin visibility concerns. AXON Q1 Earnings Miss Estimates on Tariff-Driven Margins
• Negative Sentiment: Some firms trimmed price targets (Citizens/JMP, Piper Sandler lowered targets), reflecting divergent views on valuation and risk — a potential headwind for sentiment. Citizens Jmp lowers PT (TickerReport) Piper Sandler lowers PT (TickerReport)
• Negative Sentiment: Market reaction was mixed—some coverage notes shares slipped at times despite the beat, showing investors are parsing margins, guidance details and valuation. Axon Shares Slip Despite Q1 Results Above Expectations

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Citizens Jmp lowered their target price on shares of Axon Enterprise from $825.00 to $700.00 and set a “market outperform” rating on the stock in a report on Thursday. Morgan Stanley set a $600.00 price target on shares of Axon Enterprise in a research report on Thursday. Wall Street Zen upgraded shares of Axon Enterprise from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Needham & Company LLC reduced their price target on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Finally, TD Cowen reduced their price target on shares of Axon Enterprise from $950.00 to $825.00 and set a “buy” rating for the company in a research report on Wednesday, April 8th. Sixteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $722.69.

Axon Enterprise Stock Up 10.6%

AXON opened at $426.89 on Friday. The company has a fifty day moving average price of $451.93 and a 200-day moving average price of $527.52. The firm has a market capitalization of $34.40 billion, a P/E ratio of 171.44, a price-to-earnings-growth ratio of 8.24 and a beta of 1.44. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.53 and a quick ratio of 2.29. Axon Enterprise, Inc has a one year low of $339.01 and a one year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.95%. The company had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.91 million. During the same period in the previous year, the business earned $1.47 earnings per share. The firm’s quarterly revenue was up 33.7% compared to the same quarter last year. Equities research analysts expect that Axon Enterprise, Inc will post 1.41 earnings per share for the current fiscal year.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.